Istodax’s Lymphoma Accelerated Approval Indication Falls Victim To Failed Confirmatory Trial

 
• By Sue Sutter
Dangling shoes
BMS' decision to withdraw Istodax's PTCL claim means one less accelerated approval indication dangling in the wind. • Source: Alamy

More from Review Pathways

More from Pathways & Standards